Dr Reddys Labs gets one USFDA observation for Hyderabad facility
Advertisement
Hyderabad: Pharma major, Dr Reddy's Labs, has recently announced that the United States Food & Drug Administration (USFDA) has issued a Form 483 with one observation at the completion of the inspection at the company's Bollaram facility.
The inspection was conducted from 1st May, 2023 to 5th May, 2023.
"This is to inform you that the United States Food & Drug Administration (USFDA) today completed a routine GMP inspection at our API manufacturing facility (CTO 1) in Bollaram, Hyderabad," the company stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.